Aditya Bardia

64PUBLICATIONS
318CO-AUTHORS
Haematological tumoursEconometric and statistical methodsCancer therapy (excl. chemotherapy and radiation therapy)Health and ecological risk assessmentDental therapeutics, pharmacology and toxicology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (64)

|Jun 12, 2026
Activating a B cell immune response regresses immunologically cold tumours.

|Mar 13, 2026
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.

Ann E Collier, Stephanie Hilz, Alejandro M Chibly

|Dec 17, 2025
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.

Hope S Rugo, David W Cescon, Mark E Robson

|Nov 07, 2025
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.

Maxwell R Lloyd, Caroline M Weipert, Azka Ali

|Jun 25, 2025
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer.

Aditya Bardia, Hope S Rugo, Mina S Sedrak

|Mar 28, 2025
Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer.

Aditya Bardia, Barbara Pistilli, Hope Rugo

Pageof 11

Frequent Collaborators

11 joint publications

Hope S Rugo

10 joint publications

Javier Cortes

10 joint publications

Laura Spring

10 joint publications

Dejan Juric